INSMED Inc - 8-K Filing
Insmed announced positive 12-month data from its open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension, showing sustained efficacy and safety.
Tickers: $INSM
More Regulatory news
- Boost Run Inc. - 8-K Filing
- INTERFACE INC - 8-K Filing
- Neonode Inc. - 10-Q Filing
- Virtuix Holdings Inc. - 8-K Filing
- Neonode Inc. - 8-K Filing
- Beyond Air, Inc. - 10-Q Filing
- Carter Bankshares, Inc. - 8-K Filing
- Marvell Technology, Inc. - 8-K Filing
- VISHAY INTERTECHNOLOGY INC - 8-K Filing
- LATTICE SEMICONDUCTOR CORP - 4 Filing